BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular…

Clinical Study on Reduced-Dose Pertussis Vaccine in Thailand In collaboration with Faculty of Medicine, Chulalongkorn University, BioNet has advanced a clinical study on a next-generation pertussis vaccine, featuring a reduced-dose recombinant acellular pertussis formulation—from 5 μg to 2 μg while maintaining…

BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN Jakarta, May 28, 2025 — BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia’s state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU)…